Every day, America’s biopharmaceutical sector supports the jobs of 4.7 million men and women across the country while working to discover and deliver new treatments and cures for patients across the country and around the world.
This commitment to pioneering tomorrow’s breakthroughs is felt far beyond scientists’ labs and doctors’ offices. Developing a new medicine is a collaborative endeavor that supports workers in a variety of areas, ranging from the doctors who guide patients through clinical trials to the truck drivers who deliver the final products to pharmacies. These economic effects ripple through our local, state and national economies by supporting millions of jobs and generating significant outputs in communities across the U.S.
A new report prepared for PhRMA by TEConomy Partners, LLC, highlights the substantial impact of the biopharmaceutical sector on national and local economies – how the discovery, development and delivery of innovative medicines translates into high-wage jobs, significant tax revenues and growing economic outputs for America’s communities.
Highlights from the report include:
- More than 4.7 million U.S. jobs and counting. The industry is a job multiplier – for every direct industry job there are five additional jobs indirectly supported by the industry.
- More than $1.3 trillion in economic output. In 2015, the biopharmaceutical sector produced over $584 billion in goods and services in the U.S. and supported an additional $735 billion through its vendors, suppliers and economic activity of its workforce.
- Higher annual average compensation. Employees in direct biopharmaceutical industry jobs earned an average salary of $129,527 in 2015 – that’s more than twice the national average of $58,603 for all other U.S. jobs. Americans employed by the biopharmaceutical sector earned more than $350 billion in wages and benefits.
- One-third of workers in STEM occupations. One-third of the biopharmaceutical sector’s workers are in critical science, technology, engineering and mathematics (STEM) occupations.
Over the past 30 years, the U.S. has solidified its place as the leading biopharmaceutical innovator worldwide. Today, that global leadership is propelled by innovative U.S. companies that work across a diverse and large-scale supply chain to provide patients with lifesaving and quality-of-life-improving treatments and cures. From the biopharmaceutical scientists working in labs to the employees on the front lines of manufacturing and distribution, each and every biopharmaceutical sector worker plays an instrumental role.
Learn more about the economic impacts in the U.S., each of the 50 states, the District of Columbia, and Puerto Rico. Explore the full report with detailed findings and methodology.
Nick McGee
Nick McGee is deputy vice president, public affairs, at PhRMA focusing on communications strategies and activities for the organization’s advocacy priorities.
Nick McGee
Houston’s clinical research ecosystem is building momentum
Recognizing the transformative impact of intellectual property
PhRMA Foundation makes unprecedented investment in America’s future scientific workforce
ICYMI: Pennsylvania shows what biopharmaceutical innovation can deliver
Staffing up: Building the future biopharma workforce to keep America in the lead
MFN price controls threaten American jobs and the U.S. economy
America Cures: Championing U.S. leadership in medical innovation
Middlemen mark up drug prices and keep discounts meant for you
Celebrating STEM Day: Investing in America’s innovators
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
New research: Industry sponsored clinical trials contribute billions to state economies
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
Biopharmaceutical industry supports jobs and drives economic growth across the United States
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
The Biden Administration has failed to advance an inclusive, worker-centered trade agenda
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
U.S. biopharmaceutical exports support jobs, innovation
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
The Senate’s latest price setting proposal will undermine U.S. economic growth
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
Biopharmaceutical industry drives economic growth in all 50 states
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
Beyond output and employment: The impact of America’s biopharmaceutical industry
Preserving U.S. innovation worldwide is more important than ever
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
America’s global leadership in biopharmaceutical manufacturing
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
What you need to know about H.R. 3
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
Pelosi’s radical plan leaves lung cancer patients behind
Event tomorrow: Maintaining America’s leadership in access and innovation
Pelosi’s radical plan would leave Alzheimer’s patients behind
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan
On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions
By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk
World Trade Month: How we can expand world-class pro-innovation standards
New Report: Advanced manufacturing powering innovative biopharmaceuticals
Clinical trials impact state economies
Biopharmaceutical venture capital is spurring innovation and economic growth
PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion
Researchers bring focus on science and medicine to California’s capital city
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
New PhRMA resources chock full of biopharma industry facts
New medicines are part of the solution to hold down future health care costs
New Report: America's biopharmaceutical industry supports 4.7 million jobs
Economic Impact
New Report: America's biopharmaceutical industry supports 4.7 million jobs
New Report: America's biopharmaceutical industry supports 4.7 million jobs